Misuse and abuse of pregabalin and gabapentin: Cause for concern?

CNS Drugs

Volumn 28, Issue 6, 2014, Pages 491-496

  Schifano, Fabrizio ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; CALCIUM CHANNEL; GABAPENTIN; PREGABALIN; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG MISUSE; DRUG RECEPTOR BINDING; MAXIMUM PLASMA CONCENTRATION; NERVE EXCITABILITY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; HUMAN; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS;

AMINES; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; HUMANS; PRESCRIPTION DRUG MISUSE; SUBSTANCE-RELATED DISORDERS;

EID: 84903816115     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0164-4     Document Type: Note

References (50)

1. Loftus H, Wright A. Potential misuse of pregabalin and gabapentin. BMJ. 2014;348:g1290.
2. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, Wagner X, Kiefer F, Hermann D. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;. doi:10.1007/s00228-013-1578-5.
3. Spigset O, Westin AA. Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake? Ther Drug Monitor. 2013;35:137-40.
4. Kruszewsky SP, Paczinskly RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract. 2009;15:314-9.
5. Canadian Agency for Drugs and Technologies in Health (CAD-TH). Abuse and misuse potential of pregabalin: a review of the clinical evidence; Context and policy issues; 2012. http://dpic.org/sites/default/files/PregabalinAbuse-CADTH- 24Apr2012.pdf (Accessed 20 Feb 2014).
6. British National Formulary, 2014. Gabapentin. http://www. medicinescomplete.com/mc/bnf/current/PHP2930-gabapentin.htm?q=gabapentin&t= search&ss=text&p=1#-hit (Accessed 1 Apr 2014).
7. Piskorska B, Miziak B, Czuczwar SJ, Borowicz KK. Safety issues around misuse of antiepileptics. Expert Opin Drug Saf. 2013;12:647-57.
8. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013;347:f6747.
9. Persheim MS, Helland A, Spigset O, Slørdal L. Potentially addictive drugs on reimbursable prescription for chronic severe pain. Tidsskr Nor Laegeforen. 2013;22(133):150-4.
10. Schifano F, D'Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, Di Melchiorre G, Di Furia L, Farré M, Flesland L, Mannonen M, Majava A, Pagani S, Peltoniemi T, Siemann H, Skutle A, Torrens M, Pezzolesi C, van der Kreeft P, Scherbaum N. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118-22.
11. Corkery J, Claridge H, Loi B, Goodair C, Schifano F. Drug related deaths in the UK; annual report 2013. London: International Centre for Drug Policy, St George's, University of London; 2014. ISBN: 978-1-897778-9-2.
12. Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, Rose R. Clinical outcomes in newer anticonvulsant overdose: a Poison Center observational study. J Med Toxicol. 2014 (Epub ahead of print).
13. Priez-Barallon C, Carlier J, Boyer B, Benslima M, Fanton L, Mazoyer C, Gaillard Y. Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MSin postmortem human samples: eighteen case reports. J Anal Toxicol. 2014;38:143-8.
14. Vuori E. Finland: new development in drug related deaths; 2009. https://ewsd.wiv-isp.be/Publications%20on%20new%20psychoactive%20substances/ Pregabalin/Finland%20-%20new%20develeopments%20in%20DRD.pdf (Accessed 1 Apr 2014).
15. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661-9.
16. Gajraj N. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805-15. (Pubitemid 350190582)
17. Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, De Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19:6367-74.
18. Stahl SM. Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460-1.
19. de Guglielmo G, Cippitelli A, Somaini L, Gerra G, Li H, Stopponi S, Ubaldi M, Kallupi M, Ciccocioppo R. Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addict Biol. 2012;18:644-53.
20. Richerson GB, Wu Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J Neurophysiol. 2003;90:1363-74. (Pubitemid 37129348)
21. Taylor CP, Gee NS, Su T-Z. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233-49. (Pubitemid 28137601)
22. 1H-MRS study. Neuropsychopharmacology. 2012;37:2764-71.
23. Bucur M, Jeczmien P. Pregabalin and libido. Open Neuropsychopharmacol J. 2011;. doi:10.2174/1876523801104010008.
24. Badgaiyan RD. A novel perspective on dopaminergic processing of human addiction. J Alcohol Drug Depend. 2013;1(1).
25. Modelon H, Frauger E, Laurenceau D, Thirion X, Mallaret M, Micallef J, ŕeseau des CEIP. Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network. Therapie. 2007;62:337-46. (Pubitemid 351211749)
26. Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI. Misuse of the GABA-analogues baclofen, gabapentin and pregabalin in the United Kingdom. Br J Clin Pharmacol. 2013. doi:10.1111/bcp.12277
27. Jones D, Sorkin L. Systemic gabapentin and 3-isobutyl-aminobutyric acid block secondary hyperalgesia. Brain Res. 1998;810:93-9. (Pubitemid 29003394)
28. Brighton and Hove Clinical Commissioning Group. Pregabalin prescribing policy; 2012. http://staff.brightonandhoveccg.nhs.uk/sites/default/files/ PregabalinPrescribingPolicy-Dec2012.pdf (Accessed 1 Apr 2014).
29. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin: results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-53.
30. Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2012;100:560-5.
31. Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70:197-204.
32. Dyrkorn R, Reimers A, Johannessen L, Spigset O. Do urine tests for drugs of abuse cover the substances of interest? Tidsskr Nor Laegeforen. 2011;131:570-2.
33. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2013;20:115-8.
34. Smith BH, Higgins C, Baldacchino A, Kidd B, Bannister J. Substance misuse of gabapentin. Br J Gen Pract. 2012;. doi:10.3399/bjgp12X653516.
35. Carrus D, Schifano F. Pregabalin misuse related issues; intake of large dosages, drug smoking allegations, and association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839-40.
36. Di Nicola M, Martinotti G, Tedeschi D, Frustaci A, Mazza M, Sarchiapone M, Pozzi G, Bria P, Janiri L. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol. 2010;25:268-75.
37. Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, Mazza M, Romanelli R, Moroni N, De Filippis R, Di Giannantonio M, Pozzi G, Bria P, Janiri L. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol. 2010;24:1367-74.
38. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947-57.
39. Bramness JG, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica®) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol. 2010;107:883-6.
40. Kämmerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. 2012;39:351-2.
41. Salehi M, Kheirabadi GR, Maracy MR, Ranjkesh M. Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol. 2011;31:593-6.
42. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37:1689-98.
43. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012;100:801-10.
44. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33:1582-8.
45. Howland RH. Gabapentin; can it be misused? J Psychosocial Nurs. 2014;52:12-5.
46. Sweet AD. Pregabalin abuse and the risks associated for patients with a previous history of substance misuse. J Addict Res Ther. 2013;4:e116.
47. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.
48. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110:605-7.
49. Ghodse H, Corkery J, Claridge H, Goodair C, Schifano F. Drug-related deaths in the UK: annual report 2012. Drug-related deaths reported by coroners in England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man; police forces in Scotland; & the Northern Ireland Statistics and Research Agency: annual report January-December 2011. 28 February. London: International Centre for Drug Policy, St George's University of London; 2013. http://www.sgul.ac.uk/research/projects/icdp/pdf/np-sad-13th-annual-report-2012. pdf.
50. Anonymous. Gabapentin and pregabalin: abuse and addiction. Prescrire Int. 2012;21:152-4.